# Spark Therapeutics

Clinical pipelines — Accelerated trials.

Source: https://en.bioecon.ru/companies/spark-therapeutics/
Updated: 2026-07-02

- Country: United States

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Funding | $50 million initial financing | https://www.prnewswire.com/news-releases/spark-therapeutics-launched-with-50-million-in-financing-to-advance-late--and-mid-stage-gene-therapy-programs-with-clinical-proof-of-concept-228752221.html |
| Capacity | 500,000-square-foot Gene Therapy Innovation Center under construction | https://www.pharmaceutical-technology.com/projects/spark-therapeutics-gene-therapy-innovation-center-philadelphia-usa/ |
| Certification | current good manufacturing practices (cGMP) certification for manufacturing facility | https://sparktx.com/uploads/Spark-Therapeutics-Corporate-Fact-Sheet_N-SPK-US-420038-6.pdf |
| Regulatory approval | FDA approval for LUXTURNA (voretigene neparvovec) for RPE65 mutation-associated retinal dystrophy in 2017 | https://sparktx.com/uploads/Spark-Therapeutics-Corporate-Fact-Sheet_N-SPK-US-420038-6.pdf, https://www.sec.gov/Archives/edgar/data/1609351/000160935117000114/spark-201793010xq.htm, https://www.sec.gov/Archives/edgar/data/1609351/000160935118000072/spark-201863010xq.htm |
| Production site | Philadelphia, Pennsylvania (existing facility and new Gene Therapy Innovation Center under construction) | https://sparktx.com/uploads/Spark-Therapeutics-Corporate-Fact-Sheet_N-SPK-US-420038-6.pdf, https://www.pharmaceutical-technology.com/projects/spark-therapeutics-gene-therapy-innovation-center-philadelphia-usa/ |

Independent sources: pharmaceutical-technology.com, prnewswire.com, sec.gov, sparktx.com

## Technologies

- [In-vivo gene therapy: AAV and lentiviral vectors](https://en.bioecon.ru/technology/gene-therapy-in-vivo-aav-lentiviral/)